Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
195.3 USD | +0.61% | -0.22% | -24.75% |
12:00 | Skepsis der Ärzte bremst die Einführung des Alzheimer-Medikaments in den USA | RE |
19.04. | BIOGEN INC. : Needham & Co. bleibt bei seiner Kaufempfehlung | ZM |
Kurzporträt
- Verkauf von Arzneimitteln (73,7%): zur Behandlung von Multipler Sklerose, chronischer Psoriasis bei Erwachsenen, rheumatoider Arthritis, Krebserkrankungen usw;
- Tantiemen (17,2%) ;
- Sonstige (9,1%): hauptsächlich Einnahmen aus Partnerschaftsvereinbarungen.
Mitarbeiterzahl: 7 570
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 10 173 | 100,0 % | 9 836 | 100,0 % | -3.32% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
55,2
%
| 5 532 | 54,4 % | 5 434 | 55,2 % | -1.77% |
Europe
21,8
%
| 2 413 | 23,7 % | 2 140 | 21,8 % | -11.34% |
Germany
8,8
%
| 926 | 9,1 % | 868 | 8,8 % | -6.28% |
Asia
8,8
%
| 720 | 7,1 % | 863 | 8,8 % | +19.97% |
Other
5,4
%
| 583 | 5,7 % | 531 | 5,4 % | -8.87% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 64 | 14.11.22 | |
Director of Finance/CFO | 60 | 15.08.20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 01.01.15 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 57 | 02.10.23 |
Chuck Triano
IRC | Investor Relations Contact | - | 10.04.23 |
Michael Hencke
IRO | Public Communications Contact | - | 01.07.12 |
Michael Dambach
TRE | Treasurer | 57 | 01.01.07 |
Corporate Secretary | - | - | |
Robert Kilo
PRN | Corporate Officer/Principal | - | - |
Rachid Izzar
PRN | Corporate Officer/Principal | - | 01.01.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01.01.10 |
William Hawkins
BRD | Director/Board Member | 70 | 19.06.19 |
Caroline Dorsa
CHM | Chairman | 64 | 03.01.10 |
Eric Rowinsky
BRD | Director/Board Member | 67 | 20.03.10 |
Chief Executive Officer | 64 | 14.11.22 | |
Maria Freire
BRD | Director/Board Member | 69 | 02.06.21 |
Director/Board Member | 54 | 01.01. | |
Jesus B. Mantas
BRD | Director/Board Member | 55 | 19.06.19 |
Susan Langer
BRD | Director/Board Member | - | 26.06.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 169 160 798 | 144 360 393 ( 85,34 %) | 23 800 000 ( 14,07 %) | 85,34 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
DENALI THERAPEUTICS INC. 9,16% | 12 751 365 | 9,16% | 261 658 010 $ |
SAGE THERAPEUTICS, INC. 10,38% | 6 241 473 | 10,38% | 116 965 204 $ |
14 652 466 | 7,19% | 9 817 152 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. |
Biotechnology
|
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. |
Pharmaceuticals: Major
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-24.75% | 28.22 Mrd. | |
-2.68% | 85.68 Mrd. | |
+5.53% | 41.4 Mrd. | |
+55.39% | 24.64 Mrd. | |
-5.76% | 16.98 Mrd. | |
-34.20% | 13.29 Mrd. | |
-17.18% | 11.66 Mrd. | |
-11.43% | 11.65 Mrd. | |
-0.30% | 8.18 Mrd. | |
+5.65% | 7.78 Mrd. |
- Börse
- Aktien
- 789617 Aktie
- Unternehmen Biogen Inc.